In the life science market, SDIX’s technology and capabilities are being used to help discover disease mechanisms, facilitate development of new drugs and provide antibodies and assays for the diagnosis of disease. In the food safety market, SDIX continues to expand its footprint as an international supplier of rapid pathogen test technologies that enable more accurate and cost-effective results.This news release may contain forward-looking statements reflecting SDIX's current expectations. When used in this press release, words like “anticipate,” “could,” “enable,” “estimate,” “intend,” “expect,” “believe,” “can,” “potential,” “will,” “should,” “project,” “plan” and similar expressions as they relate to SDIX are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDIX at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDIX's public filings with the U.S. Securities and Exchange Commission.
SDIX (NASDAQ: SDIX), a leading provider of In Vitro Diagnostic (IVD) reagents, announced the addition of nine new polyclonal antibodies to its product line for the IVD market while exhibiting at AACC last week. These products include Apo A1, Lp(a), HPT, CER, IgM, IgG(Fc), IgA, C3 and C4. The antibodies can be customized for in vitro diagnostics and will be available as antisera and in fractionated forms. The nine new products complement the existing SDIX IVD product line, which includes Troponin I, Strep A, CRP, ApoB and Albumin. These antibodies are used by most of the primary IVD assay companies and are estimated to represent a market of nearly $40M, according to analysis based on a Kalorama Information Report published in 2008. Immunoassay companies are currently faced with multiple challenges as they develop and expand their assay portfolio, and SDIX believes that it is strongly positioned to assist with these issues. These challenges include product quality, timely availability, supplier’s scalability, lot-to-lot consistency and platform compatibility. SDIX intends to utilize its custom development capabilities to deliver products which are superior in performance to those available in the general catalog market. “Customizing antibodies for our customers’ specific assays is one of SDIX’s core competencies. In addition to customization, we provide customers the benefit of reagent supply managed to their specific technical and business requirements,” said Paul Dany K., SDIX’s IVD Product Manager. He continued, “We anticipate that these new products will open up opportunities with new and existing customers in the near future.” For more information on these products, please contact Paul Dany K. at (302) 456-6789 or firstname.lastname@example.org. About SDIX ( www.sdix.com) SDIX is a biotechnology company with a core expertise in creating better antigens, better antibodies and better assays for the pharmaceutical, biotechnology and food safety markets. For over 20 years, SDIX has been a leading immuno-solutions company, developing results-oriented and innovative antibody-based solutions that enable customers to meet high performance research, diagnostic and commercialization objectives.